Validation of the FACT-BRM with interferon-α treated melanoma patients

Quality of Life Research

Volumn 14, Issue 1, 2005, Pages 133-139

  Paterson, Amber G ^a,e   Trask, Peter C ^b   Wagner, Lynne I ^c   Esper, Peg ^d   Redman, Bruce ^d  

^a Kaplan and Kaplan Psychologists ^*  (Canada)

^b BROWN UNIVERSITY   (United States)

^c Ctr on Outcomes Res and Education   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e Kaplan and Kaplan Psychologists   (Canada)

Author keywords

Cancer; FACT; Interferon; Melanoma; QOL

Indexed keywords

ALPHA2B INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG MEGADOSE; EMOTIONAL STRESS; FATIGUE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MELANOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RELIABILITY; SCORING SYSTEM; SIDE EFFECT; VALIDATION PROCESS;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MICHIGAN; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY;

EID: 13844272037     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-004-1694-x     Document Type: Article

References (26)

1. Aaronson NK, Ahmedzia S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993; 85: 365-376.
2. Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index - Cancer. Cancer 1988; 61: 849-856.
3. Ganz PA, Hirji K, Sim MS, Schag CA, Fred C, Polinsky ML. Predicting psychosocial risk in patients with breast cancer. Med Care 1993; 31: 419-431.
4. Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B. Baseline quality - of-life assessment in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Nat Cancer Inst 1995; 87: 1372-1382.
5. Stewart AL, Hays RD, Ware JE, et al. The MOS short-form General Health Survey: Reliability and validity in a patient population. Med Care 1988; 26: 724-735.
6. Ware JE. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: Health Institute, New England Medical Center, 1993.
7. Cella DF. The Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, Version 4. Center on Outcomes, Research, and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1997.
8. Quesada JR, Talpaz M, Rios A, Kurzrock R, and Gutterman JU. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986; 4: 234-243.
9. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of Interferon-alpha with Naltrexone. Cancer Investi 1998; 13: 561-566.
10. Kirkwood JM, Ernstoff MS. Interferons - clinical applications: Cutaneous melanoma. In De Vita VT Jr, Hellman S, Rosenberg SA (eds), Biologic Therapy of Cancer. Philadelphia, PA: J.B. Lippincott, 1991; 311-333.
11. Weiss K. Safety profile of interferon-alpha therapy. Sem Oncol 1998; 25(Suppl. 1): 9-13.
12. Eton O, Rosenblum MG, Legha SS, et al. Phase I trial of subcutaneous recombinant human Interleukin-2 in patients with metastatic melanoma. Cancer 2002; 95: 127-134.
13. Van Thiel DH, Friedlander L, De Maria N, Molloy PJ, Kania RJ, Colantoni A. Hepato-Gastroenterology 1998; 45: 328-330.
14. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18: 2316-2326.
15. Altindag A, Ozbulut O, Ozen S, Ucmak H. Interferon-alpha-induced mood disorder with manic features (Letter to the editor). Gen Hospital Psychiat 2001; 23: 168-169.
16. Gleason OC, Yates WR. Five cases of Interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40: 510-512.
17. Hauser P, Soler R, Reed S, et al. Prophylactic treatment of depression induced by Interferon-alpha. Psychosomatics 2000; 41: 439-441.
18. Soni S, Lee DS, DiVito J, et al. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and Thalidomide. J Pediatr Hematol/Oncol 2002; 24: 488-491.
19. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45: 947-950.
20. Pizzi C, Caraglia M, Cianciulli M, et al. Low-dose recombinant IL-2 induces psychological changes: Monitoring by Minnesota Multiphasic Personality Inventory (MMPI). Anticancer Res 2002; 22(2A): 727-732.
21. Trask PC, Paterson AG, Esper P, Pau J, Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high-risk melanoma receiving adjuvant interferon. Psycho-Oncology (In press).
22. Derogatis L, Melisaratos N. The Brief Symptom Inventory: An introductory report. Psychol Med 1983; 13: 595-605.
23. Derogatis L. The Brief Symptom Inventory (BSI) Administration, Scoring and Procedures Manual - II 2nd ed. Baltimore: Clinical Psychometric Research, 1992.
24. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised piper fatigue scale: Psychometric evaluation in women with breast cancer. Oncol Nursing For 1998; 25: 677-684.
25. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988; 8: 77-100.
26. Anastasi, A. Psychological Testing. (6th ed.). NY: Macmillan Publishing Company, 1988.